Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Murex challenges Chiron's monopoly

This article was originally published in Clinica

Executive Summary

Chiron has re-amended its UK HCV patent by deleting claims covering non-HCV products, thereby validating the patent. The UK Court of Appeals had found on November 2nd that the patent was only partially valid but at the hearing on November 7th to address outstanding hepatitis C patent litigation issues (see Clinica No 679, p 12), the Court allowed Chiron to re-amend the patent. As a result, the Court ruled that Murex and UBI still infringe the re-amended patent and a damage enquiry will follow.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel